sec filing
VO
NASDAQ · VOR
Vor Biopharma Inc.
Healthcare · Biotechnology
$22.32
Down-$0.76 (-3.29%)
Updated Sep 16, 2026, 7:16 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 83.27M
- P/E ratio
- -0.03
- Dividend yield
- 0.00%
- 52-week range
- $6.50 – $49.95
- Volume
- 729.85K
- Avg. volume
- 1.34M
Price performance
VOR price history
1M range · 20 trading sessions · Daily adjusted prices
VOR closed at $22.32 after 20 trading sessions, down 4.12% for the selected period.
- Last close
- $22.32
- Period change
- -4.12%
- Period low
- $22.30
- Period high
- $25.10
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $23.06 | $23.06 | $22.04 | $22.32 | 729.85K |
| Sep 14, 2026 | $22.39 | $23.56 | $22.27 | $23.08 | 888.65K |
| Sep 11, 2026 | $22.83 | $23.47 | $22.20 | $22.30 | 800.38K |
| Sep 10, 2026 | $22.96 | $23.09 | $22.09 | $22.34 | 692K |
| Sep 9, 2026 | $24.47 | $24.60 | $23.21 | $23.235 | 824.97K |
| Sep 8, 2026 | $24.75 | $26.00 | $24.10 | $25.10 | 856.98K |
| Sep 4, 2026 | $24.17 | $25.17 | $24.00 | $25.05 | 421.76K |
| Sep 3, 2026 | $24.80 | $24.94 | $23.88 | $24.24 | 538.76K |
| Sep 2, 2026 | $22.765 | $24.88 | $22.67 | $24.76 | 824.99K |
| Sep 1, 2026 | $22.32 | $22.88 | $22.0509 | $22.64 | 607.34K |
| Aug 31, 2026 | $22.50 | $22.76 | $22.28 | $22.48 | 847.99K |
| Aug 28, 2026 | $23.20 | $23.29 | $22.3792 | $22.65 | 491.05K |
| Aug 27, 2026 | $23.62 | $23.985 | $23.14 | $23.53 | 622.13K |
| Aug 26, 2026 | $23.68 | $24.09 | $23.39 | $23.67 | 448.01K |
| Aug 25, 2026 | $23.02 | $24.45 | $23.02 | $24.01 | 1.22M |
| Aug 24, 2026 | $23.12 | $23.175 | $21.90 | $22.71 | 500K |
| Aug 21, 2026 | $23.58 | $23.86 | $23.07 | $23.36 | 618.16K |
| Aug 20, 2026 | $23.05 | $23.405 | $22.79 | $23.065 | 649.62K |
| Aug 19, 2026 | $24.05 | $24.54 | $23.56 | $23.58 | 1.04M |
| Aug 18, 2026 | $22.82 | $23.845 | $22.62 | $23.28 | 1.01M |
Latest VOR news
The latest Smart Investors Daily articles mentioning VOR.
Stock researchCompany · Overview
VOR research
Overview
Company profile and research snapshot.
Company profile
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $58.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Wedbush | Neutral | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | Wedbush | Neutral | — |
| Apr 15, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2026 | Wedbush | Neutral | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.